(WKL) Wolters Kluwer - Overview
Sector: IndustrialsIndustry: Specialty Business Services | Exchange AS (Netherlands) | Currency EUR | Market Cap: 16.163m | Total Return -55.8% in 12m
Stock: Software, Information, Services, Compliance, Health
Total Rating 44
Risk 78
Buy Signal -1.36
| Risk 5d forecast | |
|---|---|
| Volatility | 26.9% |
| Relative Tail Risk | -6.47% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -2.58 |
| Alpha | -62.46 |
| Character TTM | |
|---|---|
| Beta | 0.245 |
| Beta Downside | -0.152 |
| Drawdowns 3y | |
|---|---|
| Max DD | 66.39% |
| CAGR/Max DD | -0.29 |
Description: WKL Wolters Kluwer March 04, 2026
Wolters Kluwer N.V. (WKL) provides professional information, software, and services globally. The company operates across five segments: Health, Tax & Accounting, Financial & Corporate Compliance, Legal & Regulatory, and Corporate Performance & ESG.
The Health segment delivers clinical technology and decision-making tools to healthcare providers. The Tax & Accounting segment offers solutions for tax, accounting, and audit professionals, a key market given the recurring nature of compliance needs. The Financial & Corporate Compliance segment focuses on legal entity and banking product compliance for financial institutions. The Legal & Regulatory segment provides information and workflow solutions for legal and compliance professionals, reflecting the constant evolution of regulatory landscapes. The Corporate Performance & ESG segment offers enterprise software for financial and sustainability performance, addressing growing demand for ESG reporting tools.
Wolters Kluwer also develops a platform for managing external legal costs. Further research into WKLs segment-specific product offerings and market penetration can provide deeper insights.
Headlines to watch out for
- Subscription revenue growth drives consistent financial performance
- Healthcare technology adoption boosts Health segment sales
- Regulatory changes increase demand for compliance solutions
- Corporate ESG reporting mandates expand software market
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 2.39b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.31 > 0.02 and ΔFCF/TA 6.58 > 1.0 |
| NWC/Revenue: -11.83% < 20% (prev -12.28%; Δ 0.44% < -1%) |
| CFO/TA 0.35 > 3% & CFO 3.32b > Net Income 2.39b |
| Net Debt (4.20b) to EBITDA (3.91b): 1.07 < 3 |
| Current Ratio: 0.65 > 1.5 & < 3 |
| Outstanding Shares: last quarter (230.4m) vs 12m ago -5.74% < -2% |
| Gross Margin: 68.88% > 18% (prev 0.69%; Δ 6.82k% > 0.5%) |
| Asset Turnover: 128.9% > 50% (prev 92.78%; Δ 36.16% > 0%) |
| Interest Coverage Ratio: 23.59 > 6 (EBITDA TTM 3.91b / Interest Expense TTM 125.0m) |
Altman Z'' 1.69
| A: -0.15 (Total Current Assets 2.63b - Total Current Liabilities 4.06b) / Total Assets 9.58b |
| B: 0.12 (Retained Earnings 1.17b / Total Assets 9.58b) |
| C: 0.32 (EBIT TTM 2.95b / Avg Total Assets 9.34b) |
| D: 0.14 (Book Value of Equity 1.20b / Total Liabilities 8.79b) |
| Altman-Z'' Score: 1.69 = BB |
Beneish M -2.92
| DSRI: 0.84 (Receivables 1.64b/1.36b, Revenue 12.04b/8.44b) |
| GMI: 1.00 (GM 68.88% / 68.71%) |
| AQI: 1.05 (AQ_t 0.70 / AQ_t-1 0.66) |
| SGI: 1.43 (Revenue 12.04b / 8.44b) |
| TATA: -0.10 (NI 2.39b - CFO 3.32b) / TA 9.58b) |
| Beneish M-Score: -2.92 (Cap -4..+1) = A |
What is the price of WKL shares?
As of March 30, 2026, the stock is trading at EUR 62.32 with a total of 947,115 shares traded.
Over the past week, the price has changed by -2.35%, over one month by -8.49%, over three months by -29.90% and over the past year by -55.81%.
Over the past week, the price has changed by -2.35%, over one month by -8.49%, over three months by -29.90% and over the past year by -55.81%.
Is WKL a buy, sell or hold?
Wolters Kluwer has no consensus analysts rating.
What are the forecasts/targets for the WKL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 112.9 | 81.1% |
| Analysts Target Price | - | - |
WKL Fundamental Data Overview March 30, 2026
Market Cap USD = 16.16b (14.01b EUR * 1.1537 EUR.USD)
P/E Trailing = 11.0496
P/E Forward = 11.4811
P/S = 2.2873
P/B = 18.4438
P/EG = 2.0142
Revenue TTM = 12.04b EUR
EBIT TTM = 2.95b EUR
EBITDA TTM = 3.91b EUR
Long Term Debt = 3.95b EUR (from longTermDebt, last quarter)
Short Term Debt = 778.0m EUR (from shortTermDebt, last quarter)
Debt = 5.13b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.20b EUR (from netDebt column, last quarter)
Enterprise Value = 18.21b EUR (14.01b + Debt 5.13b - CCE 932.0m)
Interest Coverage Ratio = 23.59 (Ebit TTM 2.95b / Interest Expense TTM 125.0m)
EV/FCF = 6.07x (Enterprise Value 18.21b / FCF TTM 3.00b)
FCF Yield = 16.48% (FCF TTM 3.00b / Enterprise Value 18.21b)
FCF Margin = 24.91% (FCF TTM 3.00b / Revenue TTM 12.04b)
Net Margin = 19.82% (Net Income TTM 2.39b / Revenue TTM 12.04b)
Gross Margin = 68.88% ((Revenue TTM 12.04b - Cost of Revenue TTM 3.75b) / Revenue TTM)
Gross Margin QoQ = 73.74% (prev 65.20%)
Tobins Q-Ratio = 1.90 (Enterprise Value 18.21b / Total Assets 9.58b)
Interest Expense / Debt = 0.97% (Interest Expense 50.0m / Debt 5.13b)
Taxrate = 18.11% (167.0m / 922.0m)
NOPAT = 2.41b (EBIT 2.95b * (1 - 18.11%))
Current Ratio = 0.65 (Total Current Assets 2.63b / Total Current Liabilities 4.06b)
Debt / Equity = 6.43 (Debt 5.13b / totalStockholderEquity, last quarter 798.0m)
Debt / EBITDA = 1.07 (Net Debt 4.20b / EBITDA 3.91b)
Debt / FCF = 1.40 (Net Debt 4.20b / FCF TTM 3.00b)
Total Stockholder Equity = 1.19b (last 4 quarters mean from totalStockholderEquity)
RoA = 25.56% (Net Income 2.39b / Total Assets 9.58b)
RoE = 200.3% (Net Income TTM 2.39b / Total Stockholder Equity 1.19b)
RoCE = 57.40% (EBIT 2.95b / Capital Employed (Equity 1.19b + L.T.Debt 3.95b))
RoIC = 44.40% (NOPAT 2.41b / Invested Capital 5.44b)
WACC = 5.22% (E(14.01b)/V(19.14b) * Re(6.84%) + D(5.13b)/V(19.14b) * Rd(0.97%) * (1-Tc(0.18)))
Discount Rate = 6.84% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -2.91%
[DCF] Terminal Value 87.21% ; FCFF base≈2.70b ; Y1≈2.96b ; Y5≈3.78b
[DCF] Fair Price = 476.1 (EV 111.19b - Net Debt 4.20b = Equity 106.99b / Shares 224.7m; r=6.0% [WACC]; 5y FCF grow 11.08% → 3.0% )
EPS Correlation: -10.55 | EPS CAGR: -60.51% | SUE: 0.0 | # QB: 0
Revenue Correlation: 76.36 | Revenue CAGR: 41.08% | SUE: -0.02 | # QB: 0
EPS current Year (2026-12-31): EPS=5.60 | Chg7d=-0.008 | Chg30d=-0.154 | Revisions Net=-6 | Growth EPS=+5.9% | Growth Revenue=+2.2%
EPS next Year (2027-12-31): EPS=6.25 | Chg7d=-0.009 | Chg30d=-0.129 | Revisions Net=-7 | Growth EPS=+11.6% | Growth Revenue=+6.3%
[Analyst] Revisions Ratio: -0.60 (2 Up / 8 Down within 30d for Current Year)
[Growth] Implied Growth Rate = -1.1% (Discount Rate 7.9% - Earnings Yield 9.1%)
[Growth] Growth Spread = +7.4% (Analyst 6.3% - Implied -1.1%)
P/E Trailing = 11.0496
P/E Forward = 11.4811
P/S = 2.2873
P/B = 18.4438
P/EG = 2.0142
Revenue TTM = 12.04b EUR
EBIT TTM = 2.95b EUR
EBITDA TTM = 3.91b EUR
Long Term Debt = 3.95b EUR (from longTermDebt, last quarter)
Short Term Debt = 778.0m EUR (from shortTermDebt, last quarter)
Debt = 5.13b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.20b EUR (from netDebt column, last quarter)
Enterprise Value = 18.21b EUR (14.01b + Debt 5.13b - CCE 932.0m)
Interest Coverage Ratio = 23.59 (Ebit TTM 2.95b / Interest Expense TTM 125.0m)
EV/FCF = 6.07x (Enterprise Value 18.21b / FCF TTM 3.00b)
FCF Yield = 16.48% (FCF TTM 3.00b / Enterprise Value 18.21b)
FCF Margin = 24.91% (FCF TTM 3.00b / Revenue TTM 12.04b)
Net Margin = 19.82% (Net Income TTM 2.39b / Revenue TTM 12.04b)
Gross Margin = 68.88% ((Revenue TTM 12.04b - Cost of Revenue TTM 3.75b) / Revenue TTM)
Gross Margin QoQ = 73.74% (prev 65.20%)
Tobins Q-Ratio = 1.90 (Enterprise Value 18.21b / Total Assets 9.58b)
Interest Expense / Debt = 0.97% (Interest Expense 50.0m / Debt 5.13b)
Taxrate = 18.11% (167.0m / 922.0m)
NOPAT = 2.41b (EBIT 2.95b * (1 - 18.11%))
Current Ratio = 0.65 (Total Current Assets 2.63b / Total Current Liabilities 4.06b)
Debt / Equity = 6.43 (Debt 5.13b / totalStockholderEquity, last quarter 798.0m)
Debt / EBITDA = 1.07 (Net Debt 4.20b / EBITDA 3.91b)
Debt / FCF = 1.40 (Net Debt 4.20b / FCF TTM 3.00b)
Total Stockholder Equity = 1.19b (last 4 quarters mean from totalStockholderEquity)
RoA = 25.56% (Net Income 2.39b / Total Assets 9.58b)
RoE = 200.3% (Net Income TTM 2.39b / Total Stockholder Equity 1.19b)
RoCE = 57.40% (EBIT 2.95b / Capital Employed (Equity 1.19b + L.T.Debt 3.95b))
RoIC = 44.40% (NOPAT 2.41b / Invested Capital 5.44b)
WACC = 5.22% (E(14.01b)/V(19.14b) * Re(6.84%) + D(5.13b)/V(19.14b) * Rd(0.97%) * (1-Tc(0.18)))
Discount Rate = 6.84% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -2.91%
[DCF] Terminal Value 87.21% ; FCFF base≈2.70b ; Y1≈2.96b ; Y5≈3.78b
[DCF] Fair Price = 476.1 (EV 111.19b - Net Debt 4.20b = Equity 106.99b / Shares 224.7m; r=6.0% [WACC]; 5y FCF grow 11.08% → 3.0% )
EPS Correlation: -10.55 | EPS CAGR: -60.51% | SUE: 0.0 | # QB: 0
Revenue Correlation: 76.36 | Revenue CAGR: 41.08% | SUE: -0.02 | # QB: 0
EPS current Year (2026-12-31): EPS=5.60 | Chg7d=-0.008 | Chg30d=-0.154 | Revisions Net=-6 | Growth EPS=+5.9% | Growth Revenue=+2.2%
EPS next Year (2027-12-31): EPS=6.25 | Chg7d=-0.009 | Chg30d=-0.129 | Revisions Net=-7 | Growth EPS=+11.6% | Growth Revenue=+6.3%
[Analyst] Revisions Ratio: -0.60 (2 Up / 8 Down within 30d for Current Year)
[Growth] Implied Growth Rate = -1.1% (Discount Rate 7.9% - Earnings Yield 9.1%)
[Growth] Growth Spread = +7.4% (Analyst 6.3% - Implied -1.1%)